Why Definium Therapeutics, Inc.’s (DFTX) Stock Is Up 9.31%
As of Wednesday, August 12, Definium Therapeutics, Inc.’s DFTX share price has surged by 9.31%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company’s lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
Commentary & Analysis
Why Definium Therapeutics, Inc.’s (DFTX) Stock Is Up 5.89%
As of Wednesday, August 12, Definium Therapeutics, Inc.’s DFTX share price has surged by 5.89%, which has investors questioning if this is right time to sell.Michael Rose
Why Definium Therapeutics, Inc.’s (DFTX) Stock Is Up 8.16%
As of Wednesday, August 12, Definium Therapeutics, Inc.’s DFTX share price has surged by 8.16%, which has investors questioning if this is right time to sell.Michael Rose
Why Definium Therapeutics, Inc.’s (DFTX) Stock Is Down 7.04%
As of Tuesday, August 11, Definium Therapeutics, Inc.’s DFTX share price has dipped by 7.04%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Definium Therapeutics, Inc.’s (DFTX) Stock Is Down 5.82%
As of Monday, July 13, Definium Therapeutics, Inc.’s DFTX share price has dipped by 5.82%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | DFTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6,124.8 | $620.4 | 70% |
|
| Shares Out (Mil) | 110.7 | 43.1 | 64% |
|
| Institutional Ownership | 97.5% | 84.4% | 74% |
|
| Float (Mil) | 130.6 | 47.1 | 67% |
|
| Beta | na | 0.64 | na |
|
| Avg Daily Volume (000s) | 1,870 | 304 | 79% |
|
| Price Change (52-week) |
366.5% | 67.3% | 99% |
|
| Growth | DFTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (40.2%) | (1.4%) | 9% |
|
| EPS (5yr) | (1.5%) | 14.9% | 29 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.4%) | (14.9%) | 49% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 2 | 12 | |
| Current EPS | ($0.549) | ($3.090) | ($1.525) | |
| Month Ago EPS | ($0.563) | ($2.051) | ($0.503) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.565) | ($2.051) | ($0.503) | |
| Year/Year Chg | (61.9%) | 50.1% | (88.3%) | |
| Financials | DFTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $275 | na |
|
| Net Income (TTM) (Mil) | ($354) | ($11) | 4% |
|
| EPS (TTM) | ($3.482) | ($0.600) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($168) | ($6) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $622 | $4 | 92% |
|
| Long-Term Debt (Q1) (Mil) | $37 | $6 | 37% |
|
| Enterprise Value (Q1) (Mil) | $5,077 | $466 | 64% |
|
| Valuation | DFTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.75 | 2.92 | 83% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | DFTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 65.8% | na |
|
| Net Margin | na | 0.2% | na |
|
| ROA | (51.3%) | (21.5%) | 11% |
|
| ROE | (64.1%) | (16.0%) | 13% |
|
| Liabilities to Assets | 17.5% | 34.8% | 11% |
|
| F-Score | 1 | 3 | 1% |
|
Definium Therapeutics, Inc. did not pass any screens on 8/7/2026.
